Hemoglobin and End-Organ Damage in Individuals with Sickle Cell Disease

[1]  P. Telfer,et al.  P1488: ASSOCIATION BETWEEN HEMOGLOBIN LEVELS AND END-ORGAN DAMAGE IN SICKLE CELL DISEASE: A RETROSPECTIVE LINKED PRIMARY AND SECONDARY CARE DATABASE ANALYSIS IN ENGLAND , 2022, HemaSphere.

[2]  S. Thein,et al.  Revisiting anemia in sickle cell disease and finding the balance with therapeutic approaches. , 2022, Blood.

[3]  A. Basu,et al.  Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance , 2022, Blood advances.

[4]  J. Wagner,et al.  American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation. , 2021, Blood advances.

[5]  S. Chou,et al.  Red cell transfusion and alloimmunization in sickle cell disease , 2021, Haematologica.

[6]  Suman Jain,et al.  Impact of sickle cell disease on patientsʼ daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY) , 2020, American journal of hematology.

[7]  J. Mehal,et al.  Trends in Sickle Cell Disease-Related Mortality in the United States, 1979 to 2017. , 2020, Annals of emergency medicine.

[8]  I. Agodoa,et al.  The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study , 2020, Journal of managed care & specialty pharmacy.

[9]  S. Perrotta,et al.  A study of the geographic distribution and associated risk factors of leg ulcers within an international cohort of sickle cell disease patients: the CASiRe group analysis , 2020, Annals of Hematology.

[10]  K. Ataga,et al.  Low hemoglobin increases risk for cerebrovascular disease, kidney disease, pulmonary vasculopathy, and mortality in sickle cell disease: A systematic literature review and meta-analysis , 2020, PloS one.

[11]  V. Gordeuk,et al.  Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease , 2020, PloS one.

[12]  Fares Alahdab,et al.  American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. , 2019, Blood advances.

[13]  I. Agodoa,et al.  Economic Burden of End Organ Damage Among Patients with Sickle Cell Disease in the US , 2019, Blood.

[14]  D. Lubeck,et al.  Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease , 2019, JAMA network open.

[15]  N. Shah,et al.  Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study , 2019, Health and Quality of Life Outcomes.

[16]  I. Agodoa,et al.  Opioid utilization patterns in United States individuals with sickle cell disease , 2018, American journal of hematology.

[17]  E. Vichinsky.  Chronic organ failure in adult sickle cell disease. , 2017, Hematology. American Society of Hematology. Education Program.

[18]  J. Kurtzberg,et al.  Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. , 2017, Blood.

[19]  M. Gladwin,et al.  Intravascular hemolysis and the pathophysiology of sickle cell disease , 2017, The Journal of clinical investigation.

[20]  J. Howard.  Sickle cell disease: when and how to transfuse. , 2016, Hematology. American Society of Hematology. Education Program.

[21]  G. Serjeant.  Management of sickle cell disease: challenges and risks of transfusion , 2016 .

[22]  M. Nouraie,et al.  Renal Failure in Sickle Cell Disease: Prevalence, Predictors of Disease, Mortality and Effect on Length of Hospital Stay , 2016, Hemoglobin.

[23]  M. Gladwin.  Cardiovascular complications and risk of death in sickle-cell disease , 2016, The Lancet.

[24]  Rahul Singh,et al.  Economic Impact of Sickle Cell Hospitalization , 2014 .

[25]  S. Khuder,et al.  The Diagnostic Accuracy of Doppler Echocardiography in Assessment of Pulmonary Artery Systolic Pressure: A Meta‐Analysis , 2013, Echocardiography.

[26]  M. DeBaun,et al.  High one year mortality in adults with sickle cell disease and end‐stage renal disease , 2012, British journal of haematology.

[27]  M. Beach,et al.  Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease , 2011, American journal of hematology.

[28]  J. Guh.  Proteinuria versus albuminuria in chronic kidney disease , 2010, Nephrology.

[29]  J. Panepinto,et al.  Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities , 2010, Expert review of hematology.

[30]  L. Benjamin,et al.  Definitions of the phenotypic manifestations of sickle cell disease , 2009, American journal of hematology.

[31]  P. Kavanagh,et al.  Health care utilization and expenditures for privately and publicly insured children with sickle cell disease in the United States , 2009, Pediatric Blood & Cancer.

[32]  A. Hartzema,et al.  The cost of health care for children and adults with sickle cell disease , 2009, American journal of hematology.

[33]  Scott T. Miller,et al.  Cerebrovascular accidents in sickle cell disease: rates and risk factors. , 1998, Blood.

[34]  P. Lane.  Sickle cell disease. , 1996, Pediatric clinics of North America.

[35]  G. Serjeant,et al.  Management of sickle cell disease; lessons from the Jamaican Cohort Study. , 1993, Blood reviews.

[36]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[37]  J. Niland,et al.  Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality. , 1991, Annals of internal medicine.